UTA’s Junzhou Huang secures $3.1M NIH grant to advance AI-driven antibody drug discovery, aiming to speed pandemic response and lower development costs.| Dallas Innovates
AI agents have moved from pilots to practice: 14% of large enterprises report partial or full deployments and 23% are piloting, according to the “Rise of agentic AI” report from Capgemini. But as adoption ticks up, trust in fully autonomous agents slid from 43% to 27% over the past year. What does that mix mean… The post AI agents are proliferating in pharma, but taming them may be the next frontier appeared first on Drug Discovery and Development.| Drug Discovery and Development
Artificial Intelligence (AI) has revolutionized drug discovery by assisting researchers with quick information searches. Sifting through vast databases, pattern recognition, virtual screening, and predictive modeling of new molecules has always been challenging. However, AI hallucinates up to 30% of the time, which is intolerable in the critical drug discovery domain.| Wisecube AI – Research Intelligence Platform